JP2021533203A5 - - Google Patents
Info
- Publication number
- JP2021533203A5 JP2021533203A5 JP2021529519A JP2021529519A JP2021533203A5 JP 2021533203 A5 JP2021533203 A5 JP 2021533203A5 JP 2021529519 A JP2021529519 A JP 2021529519A JP 2021529519 A JP2021529519 A JP 2021529519A JP 2021533203 A5 JP2021533203 A5 JP 2021533203A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- fusion protein
- acid sequence
- protein according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18186445.5 | 2018-07-31 | ||
| EP18186445 | 2018-07-31 | ||
| EP18204548.4 | 2018-11-06 | ||
| EP18204548 | 2018-11-06 | ||
| PCT/EP2019/070596 WO2020025659A1 (en) | 2018-07-31 | 2019-07-31 | Novel fusion protein specific for cd137 and pd-l1 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021533203A JP2021533203A (ja) | 2021-12-02 |
| JP2021533203A5 true JP2021533203A5 (enExample) | 2022-07-28 |
| JP7482488B2 JP7482488B2 (ja) | 2024-05-14 |
Family
ID=67480227
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529519A Active JP7482488B2 (ja) | 2018-07-31 | 2019-07-31 | Ｃｄ１３７とｐｄ－ｌ１に特異的な新規融合タンパク質 |
Country Status (28)
| Country | Link |
|---|---|
| US (1) | US20210363257A1 (enExample) |
| EP (2) | EP3830120B9 (enExample) |
| JP (1) | JP7482488B2 (enExample) |
| KR (1) | KR20210040103A (enExample) |
| CN (1) | CN112789292A (enExample) |
| AU (1) | AU2019315703A1 (enExample) |
| BR (1) | BR112020025263A2 (enExample) |
| CA (1) | CA3100119A1 (enExample) |
| CL (1) | CL2021000207A1 (enExample) |
| CY (1) | CY1126148T1 (enExample) |
| DK (1) | DK3830120T5 (enExample) |
| ES (1) | ES2948717T3 (enExample) |
| FI (1) | FI3830120T3 (enExample) |
| HR (1) | HRP20230590T2 (enExample) |
| HU (1) | HUE062320T2 (enExample) |
| IL (1) | IL279541A (enExample) |
| LT (1) | LT3830120T (enExample) |
| MD (1) | MD3830120T3 (enExample) |
| MX (1) | MX2021000401A (enExample) |
| MY (1) | MY200710A (enExample) |
| PH (1) | PH12021550001A1 (enExample) |
| PL (1) | PL3830120T3 (enExample) |
| RS (1) | RS64343B9 (enExample) |
| SG (1) | SG11202100989UA (enExample) |
| SI (1) | SI3830120T1 (enExample) |
| TW (1) | TWI837156B (enExample) |
| WO (1) | WO2020025659A1 (enExample) |
| ZA (1) | ZA202100125B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2022513693A (ja) * | 2018-11-29 | 2022-02-09 | ハーバー・バイオメド・セラピューティクス・リミテッド | 抗ｐｄ－ｌ１抗体製剤 |
| CN113939307A (zh) * | 2019-03-29 | 2022-01-14 | 皮里斯制药有限公司 | 脂质运载蛋白突变蛋白的吸入施用 |
| JP7634001B2 (ja) | 2019-10-11 | 2025-02-20 | ナンチン リーズ バイオラブス カンパニー，リミティド | ４－１ｂｂに結合する抗体およびその用途 |
| CA3177098A1 (en) | 2020-06-05 | 2021-12-09 | Pieris Pharmaceuticals Gmbh | Multimeric immunomodulator targeting 4-1bb |
| CN116670169A (zh) * | 2020-10-16 | 2023-08-29 | 魁尔斯弗生物治疗股份有限公司 | 与pd-l1结合的多特异性结合化合物 |
| WO2022148410A1 (zh) * | 2021-01-08 | 2022-07-14 | 北京韩美药品有限公司 | 抗pd-l1/抗4-1bb天然抗体结构样异源二聚体形式双特异抗体及其制备 |
| CN115521379B (zh) * | 2021-07-16 | 2023-12-22 | 南京吉盛澳玛生物医药有限公司 | Pd-1抗体及其用途 |
| CN115677858A (zh) * | 2021-07-23 | 2023-02-03 | 合肥瀚科迈博生物技术有限公司 | 一种能够靶向cd137和pd-l1的双特异性抗体的用途 |
| CN114736303A (zh) * | 2022-03-17 | 2022-07-12 | 英诺湖医药(杭州)有限公司 | 抗pd-l1和4-1bb的双功能抗体及其医药用途 |
| WO2023180523A1 (en) | 2022-03-24 | 2023-09-28 | Pieris Pharmaceuticals Gmbh | Process for purifying fusion proteins |
| PE20251544A1 (es) * | 2022-09-21 | 2025-06-05 | Seagen Inc | Nueva proteina de fusion especifica para cd137 y cd228 |
| CN116211860B (zh) * | 2023-05-10 | 2023-08-22 | 细胞生态海河实验室 | Ck2抑制剂cx4945在制备肿瘤治疗中防止免疫细胞耗竭药物应用、抑制剂及联合物 |
| WO2026149371A1 (zh) * | 2025-01-07 | 2026-07-16 | 四川科伦博泰生物医药股份有限公司 | 靶向pdl1/b7h3的抗体-药物缀合物及其制备方法和用途 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4946778A (en) | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
| JPH01215289A (ja) | 1988-02-22 | 1989-08-29 | Toa Nenryo Kogyo Kk | 遺伝子組換えによる正常ヒト血清アルブミンａの製造方法 |
| FR2649991B2 (fr) | 1988-08-05 | 1994-03-04 | Rhone Poulenc Sante | Utilisation de derives stables du plasmide pkd1 pour l'expression et la secretion de proteines heterologues dans les levures du genre kluyveromyces |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5728553A (en) | 1992-09-23 | 1998-03-17 | Delta Biotechnology Limited | High purity albumin and method of producing |
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| US6080560A (en) | 1994-07-25 | 2000-06-27 | Monsanto Company | Method for producing antibodies in plant cells |
| US5908621A (en) | 1995-11-02 | 1999-06-01 | Schering Corporation | Polyethylene glycol modified interferon therapy |
| US6620413B1 (en) | 1995-12-27 | 2003-09-16 | Genentech, Inc. | OB protein-polymer chimeras |
| DE19742706B4 (de) | 1997-09-26 | 2013-07-25 | Pieris Proteolab Ag | Lipocalinmuteine |
| GB9722131D0 (en) | 1997-10-20 | 1997-12-17 | Medical Res Council | Method |
| CA2233725A1 (en) | 1998-03-31 | 1999-09-30 | Hemosol Inc. | Hemoglobin-hydroxyethyl starch complexes |
| JP3839667B2 (ja) | 1998-06-08 | 2006-11-01 | エフ．ホフマン−ラ ロシュ アーゲー | 慢性Ｃ型肝炎の処置のためのＰｅｇ−ＩＮＦ−アルファ及びリバビリンの使用 |
| US6403564B1 (en) | 1998-10-16 | 2002-06-11 | Schering Corporation | Ribavirin-interferon alfa combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection |
| US7211395B2 (en) | 2001-03-09 | 2007-05-01 | Dyax Corp. | Serum albumin binding moieties |
| WO2005019255A1 (en) | 2003-08-25 | 2005-03-03 | Pieris Proteolab Ag | Muteins of tear lipocalin |
| US7288638B2 (en) | 2003-10-10 | 2007-10-30 | Bristol-Myers Squibb Company | Fully human antibodies against human 4-1BB |
| US7892827B2 (en) | 2004-11-26 | 2011-02-22 | Pieris Ag | Compound with affinity for the cytotoxic T lymphocyte-associated antigen (CTLA-4) |
| AU2006294644A1 (en) | 2005-09-27 | 2007-04-05 | Amunix, Inc. | Proteinaceous pharmaceuticals and uses thereof |
| AU2015205530B8 (en) * | 2014-01-13 | 2019-09-19 | Pieris Pharmaceuticals Gmbh | Multi-specific polypeptide useful for localized tumor immunomodulation |
| RU2727165C2 (ru) * | 2015-05-04 | 2020-07-21 | ПИЕРИС ФАРМАСЬЮТИКАЛС ГмбХ | Слитый полипептид с противораковой активностью |
| PH12017501583B1 (en) * | 2015-05-04 | 2023-01-20 | Pieris Pharmaceuticals Gmbh | Novel proteins specific for cd137 |
| DK3298030T5 (en) * | 2015-05-18 | 2024-10-07 | Pieris Pharmaceuticals Gmbh | Anti-cancerfusionspolypeptid |
| IL304871A (en) * | 2016-01-11 | 2023-10-01 | Inhibrx Inc | Multispecific and multivalent binding fusion proteins - 41BB, preparations containing them and their uses |
| RU2693661C2 (ru) * | 2016-03-04 | 2019-07-03 | Сычуань Келунь-Байотек Байофармасьютикал Ко., Лтд. | Антитело против pdl-1, его фармацевтическая композиция и применение |
| US10059769B2 (en) * | 2016-06-13 | 2018-08-28 | I-Mab | Anti-PD-L1 antibodies and uses thereof |
| WO2018087108A1 (en) * | 2016-11-09 | 2018-05-17 | Pieris Pharmaceuticals Gmbh | Proteins specific for cd137 |
| CN107082812B (zh) * | 2017-03-29 | 2018-11-13 | 上海科医联创生物科技有限公司 | 一种恢复衰竭性免疫细胞功能的融合蛋白及其应用 |
| US11421029B2 (en) * | 2017-09-01 | 2022-08-23 | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. | Recombinant bispecific antibodies to PD-L1 and CTLA-4 |
| WO2023000675A1 (zh) * | 2021-07-23 | 2023-01-26 | 安徽安科生物工程（集团）股份有限公司 | 靶向pd-l1和4-1bb的双特异性抗体 |
-
2019
- 2019-07-31 RS RS20230461A patent/RS64343B9/sr unknown
- 2019-07-31 HR HRP20230590TT patent/HRP20230590T2/hr unknown
- 2019-07-31 MD MDE20210513T patent/MD3830120T3/ro unknown
- 2019-07-31 LT LTEPPCT/EP2019/070596T patent/LT3830120T/lt unknown
- 2019-07-31 SI SI201930558T patent/SI3830120T1/sl unknown
- 2019-07-31 TW TW108127283A patent/TWI837156B/zh not_active IP Right Cessation
- 2019-07-31 MX MX2021000401A patent/MX2021000401A/es unknown
- 2019-07-31 DK DK19746089.2T patent/DK3830120T5/da active
- 2019-07-31 ES ES19746089T patent/ES2948717T3/es active Active
- 2019-07-31 CN CN201980050587.8A patent/CN112789292A/zh active Pending
- 2019-07-31 SG SG11202100989UA patent/SG11202100989UA/en unknown
- 2019-07-31 EP EP19746089.2A patent/EP3830120B9/en active Active
- 2019-07-31 CA CA3100119A patent/CA3100119A1/en active Pending
- 2019-07-31 HU HUE19746089A patent/HUE062320T2/hu unknown
- 2019-07-31 KR KR1020217006003A patent/KR20210040103A/ko not_active Ceased
- 2019-07-31 MY MYPI2020006434A patent/MY200710A/en unknown
- 2019-07-31 JP JP2021529519A patent/JP7482488B2/ja active Active
- 2019-07-31 PL PL19746089.2T patent/PL3830120T3/pl unknown
- 2019-07-31 WO PCT/EP2019/070596 patent/WO2020025659A1/en not_active Ceased
- 2019-07-31 US US17/264,080 patent/US20210363257A1/en not_active Abandoned
- 2019-07-31 EP EP23167877.2A patent/EP4249064A3/en not_active Withdrawn
- 2019-07-31 AU AU2019315703A patent/AU2019315703A1/en not_active Abandoned
- 2019-07-31 FI FIEP19746089.2T patent/FI3830120T3/fi active
- 2019-07-31 BR BR112020025263-8A patent/BR112020025263A2/pt unknown
-
2020
- 2020-12-17 IL IL279541A patent/IL279541A/en unknown
-
2021
- 2021-01-01 PH PH12021550001A patent/PH12021550001A1/en unknown
- 2021-01-07 ZA ZA2021/00125A patent/ZA202100125B/en unknown
- 2021-01-26 CL CL2021000207A patent/CL2021000207A1/es unknown
-
2023
- 2023-06-29 CY CY20231100305T patent/CY1126148T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102562519B1 (ko) | IL-15/IL-15Rα FC-융합 단백질 및 PD-1 항체 단편을 포함하는 이중특이성 이종이량체 융합 단백질 | |
| JP2018515085A5 (enExample) | ||
| RU2663795C2 (ru) | Антитело к pd-1 и его применение | |
| JP2022523524A5 (enExample) | ||
| KR102590061B1 (ko) | 유전자 조작 Fc 작제물에 관한 조성물 및 방법 | |
| JP2018519803A5 (enExample) | ||
| EP1765872B1 (en) | Glycosylated immunoglobulin and immunoadhesin comprising the same | |
| CN110234355B (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| JP2022504550A (ja) | Ｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒアルファｆｃ融合タンパク質およびその組み合わせ療法での使用 | |
| JP2018526989A5 (enExample) | ||
| CN114728040A (zh) | 新型白介素-2变体及其双功能融合分子 | |
| KR102247704B1 (ko) | 항 pd-1/항 her2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법 | |
| WO2019154349A1 (zh) | 抗pd-1/抗vegf天然抗体结构样异源二聚体形式双特异抗体及其制备 | |
| JP7359784B2 (ja) | 抗ｐｄ－１／抗ｈｅｒ２天然抗体構造ヘテロダイマー系の二重特異性抗体及びその製造方法 | |
| JP2022552183A (ja) | 特性が改善されたｐｄ－１標的化ｉｌ－１５／ｉｌ－１５ｒαｆｃ融合タンパク質 | |
| HRP20230590T2 (hr) | Novi fuzijski protein specifičan za cd137 i pd-l1 | |
| RU2018107991A (ru) | Новый слитый полипептид, специфичный в отношении lag-3 и pd-1 | |
| JP2025063025A (ja) | Ｉｇ様分子の製造のための方法および手段 | |
| JP2023550419A (ja) | 二機能性分子 | |
| TW202219068A (zh) | 包含ｉｌ—１２及抗ｆａｐ抗體的融合蛋白及其用途 | |
| CN108948207A (zh) | 一种人白细胞介素10-Fc融合蛋白及其编码基因与应用 | |
| JP2024507693A5 (enExample) | ||
| CA3204723A1 (en) | Fusions of mutant interleukin-10 polypeptides with antigen binding molecules for modulating immune cell function | |
| CN119421903A (zh) | 抗tigit抗体与il2的融合蛋白或其变体及其应用 | |
| WO2023212056A2 (en) | Combination of cytokine fusion proteins with cd8 antigen binding molecules |